- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00651911
Fasturtec TLS Treatment / Prophylysis
March 31, 2008 updated by: Sanofi
A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome
Study Overview
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chemotherapy planned for at least 3 cycles
- Undergoing cytoreductive chemotherapy for ALL, multiple myeloma or Burkitt's lymphoma stage III or IV
- With a minimum life expectancy of 3 months
- Uric acid > 8 mg%
- Negative pregnancy test < or =to 2 weeks and efficient contraceptive method.
- Negative HIV serology < or =to 4 weeks
- Patient or legal guardian has signed a written informed consent
Exclusion Criteria:
- Hypersensitivity to uricases or any of the excipients
- Known history of G6PD deficiency.
- Previous treatment with Rasburicase or Uricozyme®
- Pregnancy or lactation
- Treatment with any investigational drug within 30 days before planned first Rasburicase administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the uricolytic response to rasburicase treatment
Time Frame: 5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
|
5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate tumor lysis risk factors, treatments for tumor lysis syndrome and complications of treatment in patients treated prophylactically or therapeutically for tumor lysis syndrome
Time Frame: 5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
|
5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sharon Chang, Sanofi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Study Completion (Actual)
July 1, 2004
Study Registration Dates
First Submitted
March 28, 2008
First Submitted That Met QC Criteria
March 31, 2008
First Posted (Estimate)
April 3, 2008
Study Record Updates
Last Update Posted (Estimate)
April 3, 2008
Last Update Submitted That Met QC Criteria
March 31, 2008
Last Verified
March 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L_8637
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor Lysis Syndrome
-
Menarini GroupTerminatedTumor Lysis SyndromeSpain, Hungary, Italy, Bulgaria
-
M.D. Anderson Cancer CenterSanofiCompleted
-
SanofiCompletedCancer | Hyperuricemia | Tumor Lysis SyndromeUnited States
-
SanofiCompletedHyperuricemiaKorea, Republic of
-
M.D. Anderson Cancer CenterSanofiCompletedLymphoma | LeukemiaUnited States
-
M.D. Anderson Cancer CenterSanofiCompletedLymphoma | Leukemia | Tumor Lysis SyndromeUnited States
-
SanofiCompletedHyperuricemia | Tumor Lysis Syndrome | TumorsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Tumor Lysis SyndromeUnited States
Clinical Trials on urate oxidase
-
Shenyang Sunshine Pharmaceutical Co., LTD.Recruiting
-
The Affiliated Hospital of Qingdao UniversityRecruiting
-
University of FloridaCompleted
-
Allena PharmaceuticalsCompleted
-
Allena PharmaceuticalsCompletedChronic Kidney Diseases | Hyperuricemia | GoutUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Tumor Lysis SyndromeUnited States
-
Allena PharmaceuticalsTerminatedChronic Kidney Diseases | Hyperuricemia | GoutUnited States
-
John SundySavient PharmaceuticalsCompleted
-
Allena PharmaceuticalsCompletedHyperuricemia | GoutUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditionsUnited States